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Abstract
In malaria, CD4 Th1 and T follicular helper (TFH) cells are important
for controlling parasite growth, but Th1 cells also contribute to
immunopathology. Moreover, various regulatory CD4 T-cell subsets
are critical to hamper pathology. Yet the antigen-presenting cells
controlling Th functionality, as well as the antigens recognized by
CD4 T cells, are largely unknown. Here, we characterize the MHC II
immunopeptidome presented by DC during blood-stage malaria in
mice. We establish the immunodominance hierarchy of 14 MHC II
ligands derived from conserved parasite proteins. Immunodomi-
nance is shaped differently whether blood stage is preceded or not
by liver stage, but the same ETRAMP-specific dominant response
develops in both contexts. In naïve mice and at the onset of cerebral
malaria, CD8a+ dendritic cells (cDC1) are superior to other DC
subsets for MHC II presentation of the ETRAMP epitope. Using in vivo
depletion of cDC1, we show that cDC1 promote parasite-specific Th1
cells and inhibit the development of IL-10+ CD4 T cells. This work
profiles the P. berghei blood-stage MHC II immunopeptidome, high-
lights the potency of cDC1 to present malaria antigens on MHC II,
and reveals a major role for cDC1 in regulating malaria-specific CD4
T-cell responses.
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Introduction
Malaria is caused by parasites of the Plasmodium genus. This
disease continues to threaten nearly half of the world’s population
and to kill more than 400,000 people yearly. Malaria infection leads
to a broad spectrum of diseases with varying severity. While some
asymptomatic parasite carriers show no clinical signs, individuals
with uncomplicated malaria present mild symptoms, like fever and/
or myalgia, and severe malaria patients face deadly manifestations,
such as anemia or cerebral malaria. The diversity of human malaria
pathophysiology can be recapitulated in part using different combi-
nations of mouse backgrounds and rodent-adapted Plasmodium
species. Altogether, rodent studies have revealed the complex and
dual roles of T cells, which seem to be involved both in protection
and in pathogenesis (Freitas do Rosario & Langhorne, 2012;
Howland et al, 2015a).
CD8 T cells are essential to contain parasite development during
the initial liver stages (Frevert & Krzych, 2015; Radtke et al, 2015b).
During blood stage, when parasites reside exclusively within
erythrocytes, CD8 T cells may target MHC I-positive parasitized
erythroblasts (Imai et al, 2013) and be involved in parasite clear-
ance (Safeukui et al, 2015). Besides these protective functions, CD8
T cells play a well-established deleterious role in the vascular
pathology associated with experimental cerebral malaria (ECM). A
hallmark of ECM is the cross-presentation of parasite antigens by
endothelial cells of cerebral microcapillaries to CD8 T cells (How-
land et al, 2015b; Swanson et al, 2016). Combined to a restriction
in venous blood efflux due to cell sequestration (Nacer et al, 2014),
the CD8-mediated processes are considered pivotal in the vascular
breakdown and fatal condition.
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Being major producers of inflammatory and regulatory cytokines,
CD4 T cells are critical fine-tuners of the balance between protection
and pathology. On the one hand, CD4 T cells contribute to parasite
control. Effector memory Th1 CD4 T cells confer partial protection
in the self-resolutive Plasmodium chabaudi chabaudi (Pcc) model
(Stephens & Langhorne, 2010), and loss of T-bet, a master regulator
of Th1 differentiation, impairs control of parasitemia in the Plas-
modium berghei ANKA (PbA) model (Oakley et al, 2013). Moreover,
a subset of CD4 T cells, called T follicular helper (TFH) cells, releases
the B-cell-helping IL-21 cytokine (Perez-Mazliah et al, 2015) and is
key to promote effective germinal center formation and anti-parasite
humoral immunity (Sebina et al, 2016; Zander et al, 2016).
On the other hand, CD4 T cells also contribute to malaria-
associated pathology. By secreting IFNc in the first days of infection
(Belnoue et al, 2002; Villegas-Mendez et al, 2012), CD4 T cells
promote CXCL9- and CXCL10-dependent CXCR3-mediated accumu-
lation of CD8 T cells in the brain (Campanella et al, 2008; Van den
Steen et al, 2008). Accordingly, T-bet-deficient (Oakley et al, 2013)
and IL-12Rbeta2-deficient (Fauconnier et al, 2012) mice are less
susceptible to ECM development. In addition, production of regula-
tory cytokines, such as IL-10 (Couper et al, 2008; Freitas do Rosario
et al, 2012; Villegas-Mendez et al, 2016; Claser et al, 2017) and
IL-27 (Kimura et al, 2016), by CD4 T cells is instrumental for tilting
the balance away from pathology. Yet despite the central role of
CD4 T cells in regulating protective versus deleterious immunity
during malaria, their cognate antigens, as well as the antigen-
presenting cells (APC) controlling their differentiation, are poorly
characterized.
Chief among these APC are the dendritic cells (DC). DC concomi-
tantly act as innate sensors of pathogen motifs, activators of innate
immune cells, and initiators of the adaptive T-cell-mediated immu-
nity. DC comprise two major branches: the plasmacytoid DC (pDC)
and the conventional DC (cDC), which, based on ontogeny, can be
further subdivided into cDC1 and cDC2 (Guilliams et al, 2014).
Schematically, pDC are viewed as specialized to respond to viral
infection by producing type I IFN, and cDC are considered as the
most potent T-cell-activating cells (Durai & Murphy, 2016), even
though depending on the context, tissue, or species analyzed, these
functions may be completely or partially shared.
Early evidence suggested a functional dichotomy in antigen
presentation among cDC, with cDC1 being best-equipped for cross-
priming CD8 T cells and cDC2 preferentially activating CD4 T cells.
This specialization was proposed after specifically targeting the
same antigen to each subset (Dudziak et al, 2007). Since then, the
specific requirement for cDC1 in cross-priming CD8 T cells has been
confirmed in viral (Hildner et al, 2008; Helft et al, 2012), bacterial
(Yamazaki et al, 2013), and parasite (Mashayekhi et al, 2011; Piva
et al, 2012; Lau et al, 2014; Radtke et al, 2015a) infections. Further-
more, cDC1 are instrumental to reactivate memory CD8 T cells in
response to Listeria or virus assaults (Alexandre et al, 2016). With
respect to CD4 T-cell activation, the respective performances of
cDC1 and cDC2 seem to vary according to the context and source of
antigen. For yeast-associated antigens, cDC2 perform better than
cDC1 (Backer et al, 2008) while for cell-associated antigens, cDC1
are more potent than cDC2 (Schnorrer et al, 2006). The bacterial
antigen presentation capacity of cDC1 and cDC2 appears equivalent
when incubated with fixed bacteria (Schnorrer et al, 2006). In vivo,
some studies showed only a limited role for cDC1 in priming CD4 T
cells against a soluble antigen (Yamazaki et al, 2013) or the West
Nile Virus (Hildner et al, 2008). In agreement, cDC2 but not cDC1
are necessary for proper TFH differentiation after immunization with
allogeneic red blood cell (RBC) (Calabro et al, 2016). In contrast, in
other contexts such as during Leishmania major (Ashok et al, 2014;
Martinez-Lopez et al, 2015) and Toxoplasma gondii (Mashayekhi
et al, 2011) parasite infections, cDC1 are critical to drive Th1
responses. Of note, it has been shown in the course of a viral infec-
tion that by interacting with pre-activated CD4 T cells, cDC1 consti-
tute a platform for delivery of CD4 T cell help to CD8 T cells
(Eickhoff et al, 2015; Hor et al, 2015).
In malaria, the respective contributions of DC subsets in control-
ling CD4 T-cell activation are ill-defined. In the self-resolutive Pcc
model, cDC2 are more potent than cDC1 for MHC II presentation
of two MSP1 epitopes until day 11 post-infection, but for reasons
that were not elucidated, the trend is reversed a few days later
(Sponaas et al, 2006). In this model, a more recent study identified
a role for inflammatory monocytes in promoting Th1 responses
(Lonnberg et al, 2017). During PbA infection, MHC II presentation
by splenic cDC1 at day 3 was found to be more efficient compared
to cDC2 in one study (Lundie et al, 2010) but roughly similar to
cDC2 in another (Lundie et al, 2008). Importantly, this was evalu-
ated in BALB/c mice, which are more resistant to neuroinflamma-
tion than C57BL/6 (B6) mice (Hafalla et al, 2012), and with a
model antigen. In conclusion, the implication of DC subsets in
controlling endogenous CD4 T-cell responses during severe malaria
remains unsettled.
Here, we profiled the MHC II immunopeptidome presented by
DC to CD4 T cells during Pb infection and we engineered reporter
CD4 T-cell hybridomas specific for the most prominent
ETRAMP10.2 epitope. We report that in naı¨ve and malaria-infected
mice, cDC1 are more potent than cDC2 for presenting Plasmodium
antigens and that selective in vivo ablation of cDC1 blunts the devel-
opment of parasite-specific Th1 responses.
Results
Profiling the Plasmodium berghei-derived
MHC II immunopeptidome
Characterizing MHC II ligands and creating parasite-specific reporter
T cells are critical steps to understand the modalities of antigen
presentation and CD4 T-cell polarization during blood-stage malaria.
We used mass spectrometry to globally characterize Pb antigenic
peptides presented by MHC II on the surface of DC (Fig 1A). We
immunoprecipitated the MHC II molecules from a splenic DC tumor
cell line called MutuDC (Fuertes Marraco et al, 2012), incubated
with Pb-parasitized RBC (pRBC). Peptide-loaded MHC II are trimers
of I-Aba chain, I-Abb chain, and antigenic peptide, which, depending
on the affinity of the loaded peptide, can remain stable in SDS with-
out prior boiling (Natarajan et al, 1999). To ensure that our protocol
allowed the pull-down of peptide-MHC II trimers and not just of
single I-Abb chain, we compared the migration of eluates with and
without prior boiling, confirming that the immunoprecipitated mate-
rial was SDS-stable (Fig 1B). Although genetically very close to PbA
(Otto et al, 2014), several variants of Pb causing different patho-
physiological outcomes have been described (de Souza et al, 2010).
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Pb K173 (PbK) being the most “distant” from PbA (although SNPs
were found only in 469 of > 15,000 genes; Otto et al, 2014), we
decided to perform this analysis both with PbA and PbK pRBC. This
led to the identification of a total of 372 unique I-Ab-eluted peptides,
comprising 330 mouse sequences and 42 Pb sequences (Fig 1C,
Dataset EV1), derived from 13 putative Pb antigenic proteins (Dataset
EV2). In line with the modest level of polymorphisms between PbA
and PbK, none of those source antigens was polymorphic. Remark-
ably, for seven antigens, we recovered multiple peptides containing a
core of 11–16 amino acids (aa) and various N- or C-terminal exten-
sions (Dataset EV2). This feature is a typical property of MHC II
ligands (Bozzacco et al, 2011; Sofron et al, 2016). For each set of
nested peptides, we further analyzed the longest spanning sequence
comprising all recovered sequences, for example, NALYNYSIPR
PNVTSNL for ETRAMP10.2 (PBANKA_0517000) or LHASPYVA
PAAAIIEMAE for LDH (PBANKA_1340100), resulting in a
consolidated list of 14 peptides (Table 1). We evaluated the I-Ab bind-
ing affinity of these 14 peptides by quantifying their ability to inhibit
binding of a high-affinity radiolabeled peptide (Sidney et al, 2013).
Ten peptides were found to be good I-Ab binders (IC50 < 1,000 nM),
three moderate binders (IC50 < 5,000 nM), and one low binder
(IC50 > 5,000 nM; Table 1).
In summary, our analysis of the I-Ab immunopeptidome in DC
identifies a panel of 14 MHC II ligands derived from 13 non-
polymorphic antigenic proteins expressed by PbA and PbK.
In vivo relevance of the peptide panel during blood-stage malaria
In order to validate this panel in vivo, we measured the frequency of
CD4 T cells responding to each peptide during PbA pRBC infection
(Fig 2A). Splenic T cells were restimulated with DC loaded with an
irrelevant peptide (OVA) or uninfected RBC as negative controls,
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Figure 1. MS/MS profiling of Pb-derived MHC II immunopeptidome during blood-stage malaria.
A Experimental protocol used to immunoprecipitate MHC II molecules from PbK or PbA pRBC-loaded MutuDC and to elute MHC II-bound peptides before proteomic
analysis.
B Western blot revealed with anti-I-Abb JV2 antibody. WCL: whole-cell lysate of MutuDC + pRBC; S0: supernatant following incubation with protein-G beads; S1: 1st
wash of protein-G beads; IP MHC II: eluates from Y-3P-immunoprecipitated MHC II, boiled or not. Representative of two independent experiments.
C Venn diagram of unique peptides from P. berghei (left) and Mus musculus (right) identified in the experiments performed with PbK pRBC (blue) and PbA pRBC
(orange).
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and with PbA pRBC as positive control. The latter condition allowed
estimating the abundance of total parasite-specific CD4 T cells in the
spleen, regardless of their peptide specificity. We chose a 10:1 ratio
of pRBC to DC (Fig EV1A), and we focused on day 6 post-infection
(corresponding to ECM onset) since the parasite-specific CD4 T-cell
response was maximal at this time point and the mice succumbed
beyond this day (Fig EV1B and C). In accordance with earlier stud-
ies (Villegas-Mendez et al, 2012), we observed a substantial “spon-
taneous” release of IFNc by activated CD4 T cells (CD4+ CD11a+
CD49d+) regardless of ex vivo re-exposure to antigen (Fig 2B). In
order to improve the specificity of detection of genuine parasite-
specific CD4 T cells, we focused on double IFNc/TNF-producing
cells. Thirteen of 14 peptides elicited a higher IFNc/TNF production
than the OVA peptide, with eight showing statistical significance.
The three most dominant peptides originated from ETRAMP10.2
(NALYNYSIPRPNVTSNL, NL17), GAPDH (GINHEKYNSSQTIVSNAS,
GS18), and EF1a (SGKVVEENPKAIKSGDS, SS17) proteins (Fig 2C).
In total, CD4 T cells specific for those three peptides comprised
more than one-third of the entire PbA-specific response (Fig 2D). In
line with the inability of PbK pRBC to induce ECM at a 106 pRBC
inoculum (data not shown), the proportion of IFNc/TNF-producing
CD4 T cells in PbK-infected mice was lower. Yet the three most
dominant responses were conserved overall (Fig EV2A). This
peptide panel was also relevant in two other malaria models, in
which protection strongly relies on humoral responses. In the self-
resolutive Pcc model, six of 10 peptides tested elicited IFNc/TNF-
producing CD4 responses at day 6 post-infection (Fig EV2B). Note
that the identified ETRAMP and MSP1 peptides are not expressed
by Pcc due to sequence polymorphisms, hence the absence of
reactivity. Another model of interest is the genetically attenuated
parasite (GAP) P. berghei NK65 which lacks the histamine-releasing
factor (Pb NK65 DHRF). This vaccine strain, in which the sequences
of all identified peptides are conserved (Otto et al, 2014), causes
self-resolving blood-stage infection and results in long-lasting
cross-stage and cross-species immunity (Demarta-Gatsi et al,
2016). Three weeks post-challenge with Pb NK65 DHRF, we could
detect CD4 T cells reactive against 11 of the identified peptides
(Fig EV2C).
While injection of pRBC is a widely used model to induce blood-
stage malaria, natural infection normally starts with the inoculation
of mosquito-derived sporozoites (spz) followed by pre-erythrocytic
stages. To investigate the relevance of the peptide panel in blood-
stage responses developing after pre-erythrocytic stages, we infected
mice with PbA spz. Since liver stages last ~48 h in rodents, we
analyzed the CD4 responses at day 8 pi (Fig 3A), which is also the
time of ECM onset in this model (Fig EV1C). We first noticed that
the amplitude of the total parasite-specific CD4 response (as indi-
cated by the pRBC-loaded DC condition, Fig 3B) was ~fourfold
lower than at day 6 post-infection with pRBC (see Fig 2C). Further-
more, the immunodominance hierarchy slightly differed and this
time, the immunodominant response was targeted to the GS18
peptide from GAPDH (Fig 3B), which was the 2nd dominant peptide
after pRBC challenge. Immunodominance can be driven by different
parameters, but antigen abundance usually plays a major role.
Given that RNA-seq analysis at blood stage showed a similar and
relatively high mRNA expression for ETRAMP10.2, GAPDH, and
EF1a (>4,000 RPKM summed on all blood stages; Otto et al, 2014),
we assumed that the different immunodominance profile may be
caused by an earlier onset of GAPDH and EF1a expression during
pre-erythrocytic stages. We also hypothesized that the ETRAMP-
specific response might inflate later during blood stage developing
after spz infection. To test this possibility, we treated spz-infected
mice at days 6 and 7 with chloroquine (CQ) in order to prevent
ECM mortality but without totally blunting blood-stage development
(Fig 3A and C). We could then analyze the CD4 responses at day 14
pi, when parasitemia had reached a similar level as day 8 without
CQ (Fig 3C). In these conditions, the ETRAMP peptide was immun-
odominant (Fig 3D).
Table 1. List of synthetic peptides tested in this study and their binding affinity to I-Ab.
Gene ID Gene description
Synthetic spanning
peptide
Location in
the protein
Short peptide
name
I-Ab binding
IC50 (nM)
PBANKA_0915000 Apical membrane antigen 1 precursor INDRNFIATTALSSTEE 365–381 AMA1 818
PBANKA_0621900 Mitochondrial import inner membrane
translocase subunit TIM14
GGSTYIAAKVNEAKD 96–110 TIM14 302
PBANKA_1214300 Enolase TTLGIFRAAVPSGASTG 28–44 ENO 115
PBANKA_1326400 Glyceraldehyde 3-phosphate dehydrogenase GINHEKYNSSQTIVSNAS 135–152 GAPDH.1 2,420
PBANKA_1145900 Membrane-associated histidine-rich protein 1b TEVPSLVPPTTNTSHAAPAH 249–268 MAHRP 872
PBANKA_1133300 Elongation factor 1-alpha SGKVVEENPKAIKSGDS 369–385 EF1a 2,701
PBANKA_1410300 m1-family aminopeptidase LSEVVIHPETNYALTG 266–281 M1 15,941
PBANKA_0831000 Merozoite surface protein-1 APSEQTTTPEAATAASN 984–1,000 MSP1 1,346
PBANKA_1340100 L-lactate dehydrogenase LHASPYVAPAAAIIEMAE 231–248 LDH 110
PBANKA_0517000 Early transcribed membrane protein (ETRAMP10.2) NALYNYSIPRPNVTSNL 272–288 ETRAMP 87
PBANKA_1450300 ATP Synthase subunit beta mitochondrial DNEYDFSGKAALVYGQ 261–277 ATPSYN 104
PBANKA_0505600 Endomembrane prot 70 KILYNSAKPNSDLH 172–185 END70 478
PBANKA_0702800 Protein disulfide isomerase LIPEYNEAAIMLSEKK 65–80 PDI 166
PBANKA_1326400 Glyceraldehyde-3-phosphate dehydrogenase LMTTVHASTANQLVV 175–189 GAPDH.2 980
In the last column, IC50 values lower than 1,000 nM (corresponding to good I-A
b binders) are shown in bold.
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In summary, our results indicate (i) that CD4 immunodominance
hierarchy during blood stage is dictated in part by the route of chal-
lenge and by the duration of blood-stage infection and (ii) that
ETRAMP ultimately establishes as a prominent blood-stage peptide
after both spz and pRBC infections.
cDC1 are superior to cDC2 for I-Ab presentation of
malaria antigens
Next, we wanted to address which APC subset(s) control the gener-
ation of parasite-specific CD4 T cells by presenting malaria antigens
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Figure 2. Immunodominance of PbA-derived MHC II peptides during blood-stage malaria induced after pRBC infection.
A Experimental scheme to analyze splenic CD4 T-cell responses at day 6 following inoculation of PbA pRBC.
B Gating strategy to calculate the proportion of CD11a+ CD49d+-activated CD4 T cells that produce IFNc and TNF in response to MutuDC loaded with RBC, PbA pRBC,
OVA peptide (IR17), or ETRAMP10.2 peptide (NL17).
C Percentage of IFNc/TNF-double-producing cells among activated CD4 T cells for each peptide. Basal level with MutuDC alone was subtracted.
D Hierarchy of immunodominance, depicted as the percentage of each peptide-specific response with respect to the total parasite-specific response obtained with PbA
pRBC-loaded MutuDC.
Data information: In (C, D), data show the mean  SEM. Asterisks show statistical significance assessed by paired nonparametric Wilcoxon tests in comparison with OVA
peptide. Panel (C): AMA1, *P = 0.0098; TIM14, P = 0.078; ENO, *P = 0.016; GAPDH.1, *P = 0.002; MAHRP, *P = 0.0039; EF1a, *P = 0.0039; M1, *P = 0.016; MSP1,
*P = 0.031; LDH, P = 0.062; ETRAMP, *P = 0.001; ATPSYN, P = 0.25; END70, P = 0.25; PDI, P = 0.16; GAPDH.2, P = 0.99; pRBC, *P = 0.001. Panel (D): AMA1, *P = 0.0098;
TIM14, P = 0.16; ENO, *P = 0.016; GAPDH.1, *P = 0.002; MAHRP, *P = 0.0039; EF1a, *P = 0.0039; M1, *P = 0.016; MSP1, *P = 0.031; LDH, P = 0.062; ETRAMP, *P = 0.001;
ATPSYN, P = 0.25; END70, P = 0.25; PDI, P = 0.16; GAPDH.2, P = 0.99. N = 6 mice for ATPSYN, END70, PDI, GAPDH.2, N = 11 mice for all other peptides, pooled from three
replicates.
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on MHC II. We set out to generate reporter CD4 T-cell hybridomas
recognizing the dominant ETRAMP10.2 peptide, but as mentioned,
MHC II ligands can be diverse in size (12–25 aa) and contain vari-
ous N- and C-terminal extensions. To choose the optimal ETRAMP-
derived peptide for raising the hybridomas, we assessed the ability
of CD4 T cells from PbA-infected mice to recognize N- and C-
terminally extended versions of the NL17 peptide (Fig EV3A). As
NL17 was among the most stimulatory peptides (Fig EV3B), we
proceeded to generate NL17-specific T-cell hybridomas, that we
named B6-derived CD4 T-cell hybrids reactive to ETRAMP and
producing LacZ (BEZ). We confirmed that BEZ hybridomas reacted
to PbA pRBC- but not to uninfected RBC-loaded DC (Fig EV3C), and
we observed that BEZ detected down to 2 nM of NL17 synthetic
peptide (Fig EV3D).
To define the APC subset(s) presenting the ETRAMP10.2
peptide, we FACS-sorted three splenic DC subsets (cDC1, cDC2,
pDC) and a 4th mixed population containing macrophages and
monocyte-derived DC (moDC) from day 6-infected mice (Fig 4A)
and used them in a BEZ antigen presentation assay. cDC1 were
the most potent APC and were as stimulatory as PbA pRBC-loaded
MutuDC (Fig 4B). cDC2 were able to present the ETRAMP peptide
albeit at much lower levels. We could not detect any presentation
by pDC or by the macrophage/moDC mixed population (Fig 4B).
The lower performance of cDC2 cannot be explained by impaired
I-Ab expression since I-Ab was slightly more abundant on cDC2 in
day 6-infected mice (Fig 4C). Furthermore, when cDC1 and cDC2
were exogenously loaded with AS15, an I-Ab peptide from
T. gondii (Grover et al, 2012), there was no difference in hybri-
doma stimulation at high peptide concentration (Fig 4D). The dif-
ference between cDC1 and cDC2 in Fig 4B is likely due to other
factors, potentially including a different phagocytosis capacity
and/or a different processing efficiency. Following incubation
with heat-killed T. gondii (Fig 4E) and OVA-expressing E. coli
bacteria (Fig 4F), cDC1 were indeed more potent for processing
and presenting these exogenous antigens on MHC II. To evalu-
ate the phagocytosis potential of these two DC subsets, we
infected mice with PbA.GFP and measured the proportion of
GFP+ cells among cDC1. This proportion was about twice as
high as that among cDC2, suggesting that cDC1 possess a better
pRBC uptake capacity in vivo (Fig 4G). To analyze whether the
selective cDC1 superiority was specifically related to severe
malaria, we isolated cDC1 and cDC2 from naı¨ve mice and
exposed them to PbA pRBC (Fig 4H) and to OVA-expressing
E. coli (Fig 4I). In both contexts, cDC1 performed better than
cDC2, and again, this was not due to a reduced MHC II surface
expression (Fig 4J).
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Altogether, these data show that both in naı¨ve mice and during
severe PbA malaria, cDC2 are selectively impeded in MHC II
processing and presentation of pRBC-derived antigens as compared
to cDC1, most likely leading to cDC1 playing prominent MHC II-
related functions in vivo.
cDC1 regulate CD4 T-cell functionality during severe malaria
To decipher the in vivo implication of cDC1 in activating CD4 T cells,
we took advantage of Karma mice that allow conditional depletion of
cDC1 upon injection of DT (Alexandre et al, 2016). We first verified
that DT treatment had no adverse effect on the development of para-
sitemia and on parasite-specific Th1 responses (data not shown). We
started the DT treatment prior to infection and maintained the deple-
tion throughout blood-stage development using repeated DT injec-
tions (Fig 5A). At day 6 pi, a clear reduction in CD8a+ DC was
observed (Fig 5B and C) even though it appeared less pronounced
than what is achieved at steady state (Alexandre et al, 2016).
Regardless of the cause for this partial depletion (e.g. influence of
infection on cDC1 survival and/or differentiation), we confirmed a
previous study reporting that cDC1 promote the development of PbA-
specific CD8 responses (Piva et al, 2012). The numbers of CD8 T cells
responding to PbA pRBC-loaded MutuDC, as well as to the F4 (Lau
et al, 2011) and GAP50 (Howland et al, 2013) MHC I epitopes, were
indeed substantially lower in DT-treated Karma mice (Fig EV4A).
Most remarkably, cDC1 ablation resulted in dramatically impaired
proportions (Fig 5D and E) and numbers (Fig 5F) of CD4 T cells co-
producing IFNc and TNF in response to PbA pRBC-loaded or
peptide-pulsed MutuDC. The same was true at day 4 post-infection
(Fig EV4B) indicating that cDC1 are not only important for mainte-
nance of IFNc+ TNF+ Th1 cells but also for their priming. The
effect of cDC1 depletion on the development of Th1 CD4 responses
was not the mere consequence of altered parasite growth as blood
parasitemia was comparable with and without DT treatment
(Fig 5G). The reduced differentiation into IFNc+ TNF+ CD4 T cells
was also accompanied by further changes in the functionality of
◀ Figure 4. cDC1 are superior to other spleen antigen-presenting cells for MHC II presentation of PbA and non-PbA antigens.A Gating strategy for FACS-sorting pDC (Lin CD11clo B220+ Ly6C+), cDC1 (Lin CD11c+ CD8a+), cDC2 (Lin CD11c+ CD8a), and a mix of macrophages and moDC
(Lin CD11c CD11b+ Ly6C+) from spleens of mice infected for 6 days with PbA pRBC.
B I-Ab presentation of ETRAMP10.2 peptide by the indicated APC, measured with BEZ hybridomas. PbA pRBC-loaded MutuDC were used as controls. Representative of
two experiments with four infected mice pooled per replicate.
C Fold-change surface expression of I-Ab in cDC2 over cDC1 in day 6-infected mice (mean  SEM of five experiments). Difference is not significant based on unpaired
t-test with Welch’s correction.
D–F I-Ab presentation of non-PbA antigens by cDC isolated from day 6 PbA-infected mice. (D) I-Ab-AS15 presentation after exogenous addition of AS15 peptide at the
indicated concentrations, assessed with the BTg01Z hybridomas. (E) I-Ab-AS15 presentation by DC incubated with heat-killed T. gondii at the indicated ratio,
assessed with the BTg01Z hybridomas. (F) I-Ab-IR17 presentation by DC incubated with OVA-expressing E. coli at the indicated ratio, assessed with the OTIIZ
hybridomas. PbA pRBC-loaded MutuDC were used as controls. Representative of two experiments with four infected mice pooled per replicate. Dotted line shows
the basal response of the hybridomas in the absence of antigen.
G In vivo pRBC uptake by cDC1 (XCR1+ CD172a) and cDC2 (XCR1 CD172a+) analyzed at 6 days post-infection with PbA.GFP. Gates were positioned based on the
auto-fluorescence of the cDC subset in day 6 PbA-infected mice. As GFP+ events are rare, 107 events were acquired for each mouse. Symbols show the mean
percentage  SEM (N = 4 mice per group) of GFP+ cells in each DC subset. *P = 0.0005 by unpaired t-test without assuming consistent SD.
H, I I-Ab presentation by cDC isolated from naïve mice. (H) I-Ab-NL17 presentation by DC incubated with PbA pRBC at a ratio of 5:1, assessed with the BEZ hybridomas.
(I) I-Ab-IR17 presentation by DC incubated with OVA-expressing E. coli at a ratio of 20:1, assessed with the OTIIZ hybridomas. Representative of two independent
experiments with 20 naïve mice pooled per experiment. Dotted line shows the basal response of the hybridomas in the absence of antigen.
J Fold-change surface expression of I-Ab in cDC2 over cDC1 in naïve mice (mean  SEM of four experiments). Difference is not significant based on unpaired t-test
with Welch’s correction.
▸Figure 5. cDC1 are required for the development of parasite-specific IFNc+ TNF+ Th1 responses during PbA blood-stage malaria.A Experimental protocol to analyze T-cell responses in Karma mice at day 6 post-infection with PbA pRBC. Mice were injected with DT prior to infection and repeatedly
every 60 h thereafter.
B Gating strategy to assess efficiency of cDC1 depletion.
C Percentage (mean  SEM) of CD8a+ out of Lin B220 CD11c+ MHC IIhi cells. *P = 0.0043 by Mann–Whitney test. No DT group, N = 5 mice; + DT group, N = 6 mice.
Representative of three independent experiments.
D FACS plots showing the proportion of CD11a+ CD49d+ CD4 T cells that produce IFNc and TNF in response to MutuDC loaded with RBC, PbA pRBC, or ETRAMP10.2
peptide.
E Proportion of CD11a+ CD49d+ CD4 T cells that co-produce IFNc and TNF (mean  SEM) in response to MutuDC loaded with the indicated antigen, isolated from
Karma mice treated (open circles) or not (black circles) with DT. Asterisks show significant differences between no DT and + DT group by multiple unpaired t-tests
without assuming consistent SD. RBC, P = 0.18; GAPDH.1, *P = 0.019; EF1a, *P = 0.039; ETRAMP, *P = 0.00054; OVA, P = 0.25; pRBC, *P = 0.015. No DT group, N = 5
mice; + DT group, N = 6 mice. Representative of three independent experiments.
F Absolute numbers of IFNc+ TNF+ CD11a+ CD49d+ CD4+ T cells responding to the indicated stimuli (mean  SEM). GAPDH.1, *P = 0.0047; EF1a, *P = 0.00039;
ETRAMP, *P = 0.00022; pRBC, *P = 0.00019 by multiple unpaired t-tests without assuming consistent SD. No DT group, N = 5 mice; + DT group, N = 6 mice.
Representative of three independent experiments.
G Blood parasitemia (mean  SEM) at day 4 and 6 pi in Karma mice treated (open circles) or not (black circles) with DT. Day 4, *P = 0.022; Day 6, P = 0.77 by multiple
unpaired t-tests without assuming consistent SD. No DT group, N = 5 mice; + DT group, N = 6 mice. Representative of three independent experiments.
H Absolute numbers of CD4+ T cells producing IFNc, TNF, or IL-10, either individually or in combination, following restimulation with MutuDC+PbA pRBC
(mean  SEM). These cells are called cytokine+ in the next panels. *P = 0.0023 by unpaired t-test without assuming consistent SD. N = 3 mice per group.
I Multifunctionality analysis (IFNc, TNF, IL-10) of cytokine+ T cells responding to MutuDC loaded with PbA pRBC. N = 3 mice per group.
J Proportion of IL-10+ IFNc TNF among cytokine+ T cells, in response to MutuDC loaded with the indicated antigen (mean  SEM). GAPDH.1, P = 0.32; EF1a,
P = 0.16; ETRAMP, **P = 8.5 × 105; OVA, P = 0.11; **pRBC, P = 0.0015 by multiple unpaired t-tests without assuming consistent SD. N = 3 mice per group.
EMBO Molecular Medicine Vol 9 | No 11 | 2017 ª 2017 The Authors
EMBO Molecular Medicine cDC1 control malaria-specific CD4 Th1 Marion Draheim et al
1612
GA
PD
H.
1
EF
1a
ET
RA
MP OV
A
pR
BC
0
5
10
15
%
IL
-1
0+
ou
to
fc
yt
ok
in
e+
C
D
4+
C
D
11
a+
C
D
49
d+
no DT
+ DT
GA
PD
H.
1
EF
1a
ET
RA
MP
pR
BC
0
5×104
1×105
1×105
3×105
#
IF
N
γ+
TN
F+
C
D
4+
C
D
11
a+
C
D
49
d+
no DT
+ DT
A
B
IFNγ
TNF
(ICS)
MutuDC
RBC
PbA pRBC+
+
+
PbA pRBC
+ Peptides 
Spleen
cells
5h
+/- DT
Karma d6 pi
SS
C
-H
Lin (T,B,NK)
C
D
11
c
CD11cB220
M
H
C
 II
no DT
2.57.8
CD8α
C
D
11
b
+ DT C
D
IF
N
γ
0.2
1.9
0.1
2.9
9.1
0.4
no DT + DT
RBC
PbA
pRBC
ETRAMP
MutuDC+
RB
C
GA
PD
H.
1
EF
1a
ET
RA
MP OV
A
pR
BC
0
2
4
5
10
15
%
IF
N
γ+
TN
F+
ou
to
f
C
D
4+
C
D
11
a+
C
D
49
d+ no DT
+ DT
*
E
F G
no
DT + D
T
0
5
10
15
%
cD
C
1
am
on
g
M
H
C
IIh
i C
D
11
c+
ce
lls
*
* *
*
*
4 6
0
2
4
6
8
10
+ DT
no DT
Time (days pi)
Pa
ra
si
te
m
ia
(%
)
H
no DT + DT
I
0
5×105
1×106
2×106
#
C
D
4
pr
od
uc
in
g
cy
to
ki
ne
s
in
re
sp
on
se
to
pR
BC no DT
+ DT
J
*
**
**
IL-10 IFNg TNF IFNγ TNF
IFNγ IL-10 TNF IL-10 IFNγ TNF IL-10
*
*
*
*
TNF
Figure 5.
ª 2017 The Authors EMBO Molecular Medicine Vol 9 | No 11 | 2017
Marion Draheim et al cDC1 control malaria-specific CD4 Th1 EMBO Molecular Medicine
1613
parasite-specific CD4 T cells. Multifunctional analysis of IFNc,
TNF, IL-10 single, double, and triple producers performed on CD4
T cells responding to pRBC-loaded MutuDC (Fig 5H) showed an
increased proportion of single IL-10+ CD4 T cells in DT-treated
mice (Fig 5I). Restimulation with the three most dominant
peptides also led to higher proportions of IL-10+ Tr1 cells in
DT-treated mice (Fig 5J).
In conclusion, our data demonstrate that in the context of severe
blood-stage malaria, cDC1 promote the differentiation of parasite-
specific IFNc+ TNF+ Th1 cells, to the expense of more regulatory
IL-10+ CD4 T cells.
Discussion
In malaria-endemic areas, a nagging issue is the failure of naturally
exposed individuals to develop sterile long-lasting protective
immunity. This may be due to several factors including the stage
specificity of parasite antigen expression, the antigenic variability
among field parasites, and the profound immune dysregulation
caused by pre-erythrocytic and erythrocytic stages (Renia & Goh,
2016; Scholzen & Sauerwein, 2016; Van Braeckel-Budimir et al,
2016). These factors could also contribute to explain why despite
tremendous investments and years of research, progress on the
vaccination front has been only modest. Clinical efficacy of the most
advanced subunit vaccine candidate against P. falciparum (RTS,S)
is limited and quickly wanes over time (Olotu et al, 2016). Hopes
are emerging from whole attenuated sporozoite vaccination strate-
gies (Sissoko et al, 2017), but the disappointing RTS,S results
combined with the fact that vaccine research on P. vivax is only
beginning (Tham et al, 2017) suggest the need to broaden our
search for new subunit vaccine candidates and to dramatically
improve the candidate down-selection process.
Mouse models of malaria are not faithful in every aspect to
human malaria pathology, but they represent useful tools to estab-
lish proofs-of-concept, for example, related to immunomics
approaches. Using P. berghei infection in B6 mice, our study shows
a selective superiority of cDC1 in MHC II presentation of pRBC-asso-
ciated antigens at ECM onset, that is, day 6 post-infection. DC func-
tions are known to be impeded during blood-stage malaria
(Cockburn & Zavala, 2016), and one can imagine that malaria may
more strongly impact cDC2. However, our finding that cDC1 from
naı¨ve mice also present pRBC-derived antigens better than cDC2
suggests that this difference is not, or at least not solely, dictated by
infection. Using a CD4 T-cell hybridoma that recognizes a currently
undefined Plasmodium epitope, a Biorxiv-posted study (Fernandez-
Ruiz et al, 2017) reports that cDC1 are more stimulatory than CD4+
DC and double-negative DC, both in naı¨ve mice and at 3 days post-
infection. Although the sensitivity of our hybridomas did not allow
us to evaluate the ETRAMP10.2 MHC II presentation at such an
early time point (data not shown), our data are consistent with this
work. What mechanism(s) could account for such a difference in
MHC II presentation? One possibility is that cDC1 are equipped with
a better pRBC uptake capability, which is supported by our evalua-
tion of pRBC uptake in day 6-infected mice. In line with this idea,
the phagocytic potential of cDC2 is specifically suppressed by type I
IFN signaling during PbA infection (Haque et al, 2014). Another
non-mutually exclusive hypothesis is a difference in the efficiency of
the MHC II processing pathway. Phagolysosome maturation and/or
hydrolase activity in MHC II processing compartments could be
selectively enhanced in cDC1 and/or dysfunctional in cDC2. Alter-
natively, antioxidant pathways involving heme oxygenase-1, which
are known to affect antigen presentation by DC (Riquelme et al,
2015), may be differentially elicited in cDC1 vs cDC2. Dissecting
how malaria antigens are processed differentially for MHC II presen-
tation in DC subsets, and how severe malaria regulates this process,
represents exciting avenues of future research.
A second substantial finding is that during severe malaria, cDC1
are critical for priming and promoting parasite-specific Th1 CD4 T
cells. This is consistent with the results of a study using a CD4
TCR-transgenic mouse specific for a Plasmodium epitope (Fernandez-
Ruiz et al, 2017). More generally, these data are in line with the
established propensity of cDC1 to secrete IL-12 during infection by
intracellular pathogens (Mashayekhi et al, 2011; Alexandre et al,
2016) and the implication of cDC1 in Th1 polarization during other
parasitic infections such as leishmaniasis (Ashok et al, 2014;
Martinez-Lopez et al, 2015) and toxoplasmosis (Mashayekhi et al,
2011). Perhaps most importantly, we find that cDC1 depletion,
possibly by “forcing” MHC II presentation by the remaining cDC2
subset, skews cytokine production of parasite-specific CD4 T cells
toward a more regulatory profile, associated with a higher propor-
tion of single IL-10-producing CD4 T cells. This supports the emerg-
ing and prominent concept that functional polarization of CD4 Th
cells is in part dictated by the subset(s) of cDC activating the CD4 T
cells (Dutertre et al, 2014; Vu Manh et al, 2015). For instance, while
IRF4 deficiency (resulting in impaired migration of cDC2) abrogates
Th17 responses upon fungal challenge, Batf3 deficiency (resulting in
lack of cDC1) skews CD4 responses toward Tregs and Th2, ulti-
mately perturbing Leishmania parasite control (Ashok et al, 2014).
In a non-infectious context, a mouse model of type I diabetes, target-
ing of a pancreatic cell antigen to cDC2 favors tolerogenic properties
by autoreactive CD4 T cells as compared to cDC1 targeting (Price
et al, 2015). Given the major regulatory role of IL-10 produced by
CD4 Th cells during Pcc infection (Freitas do Rosario & Langhorne,
2012), one could speculate that the sustained antigen presentation
by cDC2 in this setting (Sponaas et al, 2006) is involved in prevent-
ing immunopathology. In turn, one could hypothesize that addition
of cDC2 or restoration of cDC2 MHC II presentation during PbA
infection may mirror cDC1 depletion and enhance the differentiation
of regulatory Tr1 cells, which could ultimately alleviate ECM
immunopathology. Harnessing DC subsets for immunotherapy of
rheumatoid diseases (Pozsgay et al, 2017) and autoimmune
pathologies (Liu & Cao, 2015; Audiger et al, 2017) is already a major
research area. Modulating cDC1 to curtail excessive Th1 responses
in human severe malaria could represent a valuable translational
approach.
So far at least eight MHC I epitopes were characterized in B6
mice infected with PbA (Lau et al, 2011, 2014; Howland et al, 2013;
Poh et al, 2014), but no CD4 T-cell epitope was known. By charac-
terizing the MHC II immunopeptidome by MS/MS, our study identi-
fies a panel of MHC II ligands able to restimulate CD4 T cells
isolated from PbA-infected mice. PbA infection is suited to evaluate
the role of DC on T-cell polarization and pathogenicity during cere-
bral malaria, but this acute model is not well adapted to study the
effects of CD4-dependent antibody responses on parasitemia. As
previously reported (Piva et al, 2012), we observed no major effect
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of cDC1 depletion on parasite growth. Pcc and Pb NK65 DHRF are
likely to be better models to evaluate the relevance of the identified
peptides on parasitemia and antibody-mediated protection. While
our study does not analyze these aspects, we found that some
peptides were recognized by CD4 T cells isolated from Pcc-infected
mice and mice immunized with the Pb NK65 DHRF GAP, thus
setting the stage to assess (i) whether the conserved peptides will
elicit protection after challenge with Pcc and (ii) whether the protec-
tive antibody responses generated by the Pb NK65 DHRF vaccine
GAP target the same MHC II antigens. Among the unraveled antigen
panel, two of them may be particularly relevant to further analyze:
ETRAMP10.2 and GAPDH. ETRAMP10.2 belongs to a family of
proteins present in mouse and human Plasmodium that is secreted
and anchored at the parasitophorous vacuole membrane (Spielmann
et al, 2003; Pasini et al, 2013). Interestingly, ETRAMP10.2 and other
members (ETRAMP2, 4 and 10.1) are recognized by immunoglobu-
lins from individuals living in a high-endemicity malaria region of
Papua New Guinea (Spielmann et al, 2003) and ETRAMP11.2 is
recognized by sera from > 80% of P. vivax-exposed individuals
(Chen et al, 2015), showing that ETRAMPs are relevant B-cell anti-
gens in humans. GAPDH is primarily involved in glycolysis, but this
enzyme also functions in processes ranging from DNA repair to
membrane trafficking, iron transport, and cell signaling (Perez-Casal
& Potter, 2016). Akin to other housekeeping proteins, it had long
been assumed that GAPDH was present exclusively in the cyto-
plasm, but accumulating evidence suggests that it is also present at
the surface of pathogens such as Schistosoma mansoni helminths
(Argiro et al, 2000) and Streptococcus bacteria, where it could
modulate virulence (Jin et al, 2011). Interestingly, resistance to
S. mansoni reinfection was found to correlate with serum reactivity
toward a GAPDH epitope (Argiro et al, 2000). In this context,
GAPDH has been proposed as a vaccine candidate in several infec-
tious settings and animal models (Perez-Casal & Potter, 2016).
During malaria, GAPDH is expressed during asexual blood stage at
the apical end of merozoites where it may be involved in membrane
trafficking and vesicular transport (Daubenberger et al, 2003). Anal-
ysis of the surface-exposed spz proteome (Swearingen et al, 2016)
and immunofluorescence assays (Cha et al, 2016) revealed that
GAPDH is expressed on the surface of P. falciparum and of
P. berghei spz. Notably, surface GAPDH interacts with CD68
expressed on Kupffer cells and is involved in liver invasion (Cha
et al, 2016). Furthermore, immunization of Swiss-Webster mice
with KLH-coupled GAPDH conferred protection after spz challenge
(Cha et al, 2016). Knowing that the GAPDH GS18 epitope is
conserved in PbA, PbK173, PbNK65, Py17XNL, and Pcc, it seems
relevant to further investigate the value of GAPDH as a multistage
invasion-blocking vaccine candidate in pre-clinical mouse models.
Our data also suggest analyzing whether natural antibody responses
targeting Plasmodium GAPDH in humans are associated with a
certain degree of immunity and/or clinical protection.
At last, our work provides a proof-of-concept supporting the
relevance of profiling the HLA class II immunopeptidome for
blood-stage P. falciparum. The biological and mass spectrometry
techniques to analyze immunopeptidomes are rapidly evolving
(Caron et al, 2015) and methods to characterize HLA DR-bound
immunopeptidomes with relatively low numbers of cells have been
optimized (Heyder et al, 2016), supporting the feasibility of this
approach in human malaria. We expect this to lead to the
identification of naturally processed epitopes recognized by CD4 T
cells, including TFH, in infected humans. CD4 T cell help to CD8 T
cells is needed to generate robust memory CD8 T cells (Janssen
et al, 2005), and the ability to generate fully functional TFH is criti-
cal for maintenance of effective long-term humoral immunity
against malaria (Hansen et al, 2017). Thus, applying this approach
in human malaria may both uncover new vaccine targets and help
us down-select vaccine candidates that are more likely to drive
robust antibody responses through TFH restimulation and long-
lasting CD8 T-cell memory differentiation through DC-integrated
CD4 help.
Materials and Methods
Ethics statement
Animal care and use protocols were carried out under the control of
the National Veterinary Services and in accordance with the Euro-
pean regulations (EEC Council Directive, 2010/63/EU, September
2010). The protocol (CE no. 2015-03) was approved by the local
Ethical Committee for Animal Experimentation (registered by the
“Comite´ National de Re´flexion Ethique sur l’Expe´rimentation
Animale” under no. CEEA122).
Mice, parasites, and experimental infections
C57BL/6J (B6) were purchased from Janvier (France), and Karma
mice (a530099j19rik-tm1Ciphe; Alexandre et al, 2016) were imported
from CIPHE, Marseille, France. All mice were males between 7 and
16 weeks old. They were housed under specific pathogen-free condi-
tions at UMS006-CREFRE, Toulouse. Plasmodium berghei ANKA
(PbA) and P. berghei Kyberg 173 (PbK) parasites were propagated in
B6. To prepare pRBC stocks, mice were bled in heparin and the
proportion of pRBC was evaluated by blood smear. pRBC concentra-
tion was adjusted to 107 pRBC/ml in Grau solution (Alsever’s solution
with 10% glycerin), and 1 ml aliquots were stored at 80°C. All pRBC
infections were done by intravenous inoculation of 106 pRBC, unless
otherwise indicated. Sporozoites were obtained from salivary glands
of Anopheles stephensi mosquitoes infected with PbA expressing GFP
under the HSP70 promoter, as described (Manzoni et al, 2014). In
brief, A. stephensi mosquitoes were reared at 26°C and 80% humid-
ity, and fed on 10% sucrose solution. Adult mosquitoes from 3 to
7 days were fed on anesthetized PbA-infected mice and further kept at
21°C. Salivary glands of PbA-infected mosquitoes were removed by
hand dissection 21–28 days post-feeding and crushed in Leibovitz’s
L-15 medium to release sporozoites. Parasites were counted and kept
at 4°C until use. Mice were infected i.v. with 5 × 104 spz.
Parasitemia was measured by blood smear or flow cytometry
with similar results. For flow cytometry, 3 ll of blood tail was
collected using a microvette. With PbA.GFP, the percentage of pRBC
was determined by gating on GFP+ out of total RBC on non-fixed
blood. With non-fluorescent parasites, the blood was labeled with
Ter119-FITC (1/30, Miltenyi Biotec), CD71-PE (C2, 1/300, BD
Pharmingen) and CD41-PE-Cy7 (MWReg30, 1/100, Biolegend), fixed
and permeabilized in 4% PFA and 0.6% saponin followed by DAPI
staining. The percentage of pRBC was determined by gating on
DAPI+ out of Ter119+ CD41 cells.
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MutuDC loading, I-Ab immunoprecipitation, and peptide elution
pRBC from freshly harvested blood were enriched using Percoll in
order to obtain > 70% parasitemia. 108 MutuDC were incubated
overnight with 109 PbA or PbK pRBC at 37°C. Loaded DC were lysed
using CHAPS buffer during 45 min at 4°C, as previously described
(Bozzacco & Yu, 2013). The lysate was cleared by centrifugation at
14,000 g for 15 min, and MHC II molecules were immunoprecipi-
tated from the cleared lysate using 50 lg of Y-3P antibody (BioX-
Cell) bound to protein-G beads overnight at 4°C. Beads were
washed 3 times, and peptides were eluted with 10% acetic acid at
70°C for 10 min.
Western blot
Immunoprecipitation eluates were reduced in b-mercaptoethanol
and boiled or not in Laemmli buffer. Lysates corresponding to
7.5 × 105 DC equivalents were separated by electrophoresis on 10%
polyacrylamide gels and transferred to nitrocellulose membranes.
Immunologic detection was achieved using primary rabbit anti-
mouse I-Ab (JV2, 1/1,000) followed by horseradish peroxidase-
conjugated mouse anti-rabbit antibodies (Promega). Detection
of peroxidase activity was achieved using a ChemiDoc system
(Bio-Rad).
Nano-LC-MS/MS analysis
Prior to analysis, peptides were separated from protein using a
Vivaspin concentrator with 10-kDa MW cutoff. Peptides were
subjected to solid-phase extraction using a C18 Sep-Pak cartridge
and finally concentrated using a rotating evaporator. Nano-LC-MS/
MS analysis was performed on an UltiMate 3000 RSLCnano System
(Thermo Fisher Scientific) coupled to a Q-Exactive mass spectrome-
ter (Thermo Fisher Scientific). Peptides were automatically fraction-
ated onto a C18 reverse-phase column (75 lm × 150 mm, 2 lm
particle, PepMap100 RSLC column, Thermo Fisher Scientific) at a
temperature of 35°C. Trapping was performed during 4 min at
5 ll/min, with solvent A (98% H2O, 2% ACN and 0.1% FA).
Elution was performed using two solvents A (0.1% FA in water)
and B (0.1% FA in ACN) at a flow rate of 300 nl/min. Gradient
separation was 36 min from 2% B to 40% B, 2 min to 90% B, and
maintained for 5 min. The column was equilibrated for 13 min with
5% buffer B prior to the next sample analysis. The electrospray volt-
age was 1.9 kV, and the capillary temperature was 275°C. Full MS
scans were acquired over m/z 400–2,000 range with resolution
70,000 (m/z 200). The target value was 106. Ten most intense peaks
with charge state between 2 and 7 were fragmented in the HCD
collision cell with normalized collision energy of 35%, and tandem
mass spectrum was acquired with resolution 35,000 at m/z 200.
The target value was 2 × 105. The ion selection threshold was
6.7 × 104 counts, and the maximum allowed ion accumulation
times were 250 ms for full MS scans and 150 ms for tandem mass
spectrum. Dynamic exclusion was set to 30 s.
Proteomic data analysis
Raw data collected during nano-LC-MS/MS analyses were processed
and converted into *.mgf peak list format with Proteome Discoverer
1.4 (Thermo Fisher Scientific). MS/MS data were interpreted using
search engine Mascot (version 2.4.1, Matrix Science, London, UK)
installed on a local server. Searches were performed with a toler-
ance on mass measurement of 0.02 Da for precursor and 10 ppm for
fragment ions, against a composite target decoy database (189,576
total entries) built with Plasmodium berghei UniProt database
(TaxID = 5,823, December 3, 2015, 13,853 entries), Mus musculus
UniProt database (TaxID = 10,090, December 3, 2015, 78,986
entries) fused with the sequences of recombinant trypsin and a list
of classical contaminants (117 entries). Methionine oxidation and
protein N-terminal acetylation were searched as variable modifi-
cations, and no enzyme was indicated. For each sample, peptides
were filtered out according to the cutoff set for proteins hits with 1
or more peptides taller than nine residues and ion score > 19, allow-
ing a false-positive identification rate of 2.5% for protein and 0.4%
for peptides.
MHC purification and binding assays
Purification of I-Ab MHC II molecules by affinity chromatography
and the assay based on the inhibition of binding of a high-affinity
radiolabeled peptide to quantitatively measure peptide binding were
described elsewhere (Sidney et al, 2013). Briefly, the mouse B-cell
lymphoma LB27.4 was used as a source of MHC molecules. A high-
affinity radiolabeled peptide (0.1–1 nM; peptide ROIV, sequence
YAHAAHAAHAAHAAHAA) was co-incubated at room temperature
with purified MHC in the presence of a cocktail of protease inhibi-
tors and an inhibitor peptide. Following a 2-day incubation, MHC-
bound radioactivity was determined by capturing MHC/peptide
complexes on mAb (Y3JP)-coated Lumitrac 600 plates (Greiner Bio-
one), and measuring bound cpm using the TopCount (Packard
Instrument Co) microscintillation counter. The concentration of
peptide yielding 50% inhibition of the binding of the radiolabeled
peptide was calculated. Under the conditions utilized, where
[label] < [MHC] and IC50 ≥ [MHC], the measured IC50 values are
reasonable approximations of the true Kd values. Each competitor
peptide was tested at six different concentrations covering a
100,000-fold range. The “cold” probe was used as a positive control
in each experiment.
Generation of reporter CD4 T-cell hybridomas
Mice were infected with PbA pRBC and treated with intraperitoneal
injections of 0.4 mg of chloroquine (CQ) at days 3, 4, 5, and 6 pi.
Spleens were harvested at day 7 pi, and 6 × 106 splenocytes were
seeded per well into a P24 in complete RPMI medium supplemented
with 1 lM of ETRAMP NL17 peptide. After 2 days, 50 U/ml of
recombinant human IL2 (rhIL2, BD Biosciences) was added. After
1 week, cells were separated by Ficoll and CD4 T cells were
enriched using magnetic sorting (Miltenyi). CD4 T cells were tested
for reactivity and put back in culture with 35 Gray-irradiated
MutuDC, 1 lM of NL17, 50 U/ml rhIL2, and 5% of T-stim solution.
Three days after, T-cell cultures were subjected to Ficoll separation
and fused with the TCRab-negative lacZ-inducible BWZ fusion part-
ner, as previously described (Feliu et al, 2013). Hybridomas were
selected and subcloned at least 3 times. The reactivity was tested by
mixing 105 hybridomas with 5 × 104 MutuDC or BMDC, previously
loaded with varying ratios of pRBC or RBC extracts overnight, or
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incubated with serially diluted NL17 peptide. RBC extracts were
obtained by three freeze/thaw cycles (liquid nitrogen/37°C).
TCR-triggered stimulation of the hybridomas was quantified
using a chromogenic substrate: chlorophenol red-b-D-galactopyra-
noside (CPRG, Roche). Cleavage of CPRG by b-galactosidase
releases a purple product, which absorbance was read at 595 nm
with a reference at 650 nm.
Ex vivo spleen T-cell restimulations
Spleens from infected mice were collected, mashed on a 70-lm cell
strainer in RPMI supplemented with 10% of FBS and treated with
RBC lysis buffer (ACK: 100 lM EDTA, 160 mM NH4Cl, and 10 mM
NaHCO3). 10
6 spleen cells were incubated for 5 h at 37°C in the
presence of brefeldin A with 105 DC with or without 5 lM of
peptide, or with pRBC-loaded DC. Intracellular IFNc (IFNc-APC,
XMG1.2 1/500 BD Pharmingen), TNF (TNF-AF700, MP6-XT22
1/300 BD Pharmingen), and IL-10 (IL10-BV650, JES5-16E3 1/300
BD Horizon) were detected with Cytofix/Cytoperm kit (BD Pharmin-
gen) or Intracellular Fixation and Permeabilization Buffer Set (eBio-
science). In addition to the newly identified PbA peptides, we used
the following control peptides: OVA/IR17 (ISQAVHAAHAEINEAGR)
and T. gondii AS15 (AVEIHRPVPGTAPPS) restricted by I-Ab, F4
(EIYIFTNI; Lau et al, 2011), and GAP50 (SQLLNAKYL; Howland
et al, 2013) restricted by Kb and Db, respectively.
Analysis and ex vivo isolation of spleen APC subsets
Spleens were perfused with collagenase D (1 mg/ml) and DNAse I
(0.1 mg/ml), cut into small pieces and incubated at 37°C for
45 min. Cell preparations were filtered using 100-lM cell strainers,
and APC populations were enriched using magnetic depletion of B,
NK, and T cells (Miltenyi). For experiments that focused only on
cDC, cDC were enriched using CD11c-positive selection (Miltenyi).
Cell suspensions were labeled with the following antibodies: CD3-
APC (145-2C11, 1/300 eBioscience), CD19-APC (ID3, 1/300 Biole-
gend), NK1.1-APC (PK136, 1/300 BD Pharmingen), B220-BV510
(RA3-6B2, 1/500, BD Horizon), CD11b PE-CF594 (M1/70, 1/3000
BD Horizon), CD11c PE-Cy7 (HL3, 1/400 BD Pharmingen), Ly6C-
PerCP-Cy5.5 (AL-21, 1/1000 BD Pharmingen), CD64 BV421 (X54-5/
7.1, 1/300 Biolegend), CD8a APC-Cy7 (53-6.7, 1/200 BD Pharmin-
gen), or XCR1-PE (REA707, 1/100 Miltenyi). Cells were sorted on a
BD AriaSorp (BD Biosciences) with purity routinely higher than
95%. Expression of MHC II was assessed in a separate mix since the
anti-I-Ab AF700 (M5/114, 1/500 BD Pharmingen) is a blocking anti-
body. For experiments with Karma mice in which cDC1 are
Tomato+, CD11b-PerCP-Cy5 (M1/70, 1/200 BD Pharmingen) was
used. All flow cytometry samples were run on a Fortessa (BD
Biosciences) and analyzed using FlowJo software.
Ex vivo antigen presentation assays
FACS-sorted APC were serially diluted into 96-W round-bottom
plates and mixed with 105 T-cell hybrids/well. For non-PbA anti-
gens, 5 × 104 FACS-sorted DC per well were seeded in a 96-W
round-bottom plate and treated as follows. To readout presentation
of heat-killed T. gondii, RH tachyzoites were treated for 15 min at
56°C in PBS and incubated with DC for 3 h before adding BTg01Z
hybrids (Grover et al, 2012). To readout presentation of OVA-
expressing E. coli, an overnight pre-culture of DH5a transformed
with pGEX.4T1.OVA was transferred to 7 ml of LB medium contain-
ing 100 lg/ml ampicillin and grown for 1 h. IPTG was added, and
bacteria were grown for 4 more hours at 30°C. Bacteria were
counted, washed, suspended in antibiotic-free serum-free RPMI, and
incubated with DC at the indicated MOI for 40 min. After washing,
gentamycin (100 lg/ml) was added for 3 h followed by incubation
with 105 OTIIZ/well (Sahara & Shastri, 2003). For exogenous
peptide loading, the T. gondii I-Ab peptide (AS15) was added to the
DC simultaneously with the BTg01Z hybrids.
Statistical analyses
The Prism software (GraphPad) was used for statistical analyses. To
compare each peptide to the OVA peptide in ex vivo restimulation
assays, nonparametric paired t-tests (Wilcoxon) were used. For
other comparisons, unpaired t-tests without assuming consistent SD
(Welch’s correction) were used.
Data deposition
The mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE partner repository with
the dataset identifier PXD007628.
Expanded View for this article is available online.
The paper explained
Problem
Malaria is a parasitic disease causing life-threatening complications
like cerebral malaria. Natural protective immunity takes years to
develop, and the efficacy of currently developed vaccines is limited.
During malaria, the immune cross talk between dendritic cells (DC)
and T cells prompts CD4 T cells to differentiate into functionally
distinct subsets, which control the fate of memory CD8 T cell and
antibody responses and ultimately determine the balance between
parasite control and immunopathology. A major aim is to improve
protective immunity without exacerbating immunopathology. To do
this, one needs to elucidate how DC control the functionality of para-
site-specific CD4 T cells.
Results
We work with a mouse malaria model induced by Plasmodium
berghei. We use proteomics to identify parasite MHC class II antigens
that elicit CD4 T cells in infected mice, as well as in long-term
protected mice vaccinated with an attenuated parasite. We find that
a peculiar DC subset, named cDC1, is superior for MHC II presentation
of Plasmodium-derived antigens. We further show that cDC1 promote
the differentiation of a type of parasite-specific CD4 T cells that play
a pathogenic role in cerebral malaria (Th1) and that they inhibit the
development of regulatory IL-10+ CD4 T cells.
Impact
Our work sets the stage for MHC II immunopeptidome profiling in
blood-stage human malaria. This should help uncover new vaccine
targets and down-select vaccine candidates. Our study also supports
the idea of harnessing DC functions to curtail excessive Th1 responses
in human severe malaria.
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